Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 821-827

  Destro, Maurizio ^a   Crikelair, Nora ^b   Yen, Joseph ^b   Glazer, Robert ^b  

^a Azienda Ospedaliera della Provincia di Pavia   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amlodipine; HCTZ; Stage 2 hypertension; Triple therapy; Valsartan

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; HYDROCHLOROTHIAZIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADD ON THERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CAUCASIAN; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLUSHING; HUMAN; HYPERTENSION; HYPOKALEMIA; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NECK PAIN; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PERIPHERAL EDEMA; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SECONDARY ANALYSIS; SIDE EFFECT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; MIDDLE AGED; TREATMENT OUTCOME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79952061117     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S11522     Document Type: Article

References (29)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
2. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-1762.
3. Ong KL, Cheung BM, Man YB, Lau C P, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in fve European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
5. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
6. Sica DA. Current concepts of pharmacotherapy in hypertension - fxed dose combination antihypertensive therapy: is this the future? J Clin Hypertens (Greenwich). 2000;2(1):46-53.
7. Sica DA. Rationale for fxed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443-462.
8. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
10. Mancia G, Brown M, Castaigne A, et al. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension. 2003;41(3):431-436.
11. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007;9(5):355-364.
12. Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin. 2007;23(2):259-270.
13. Bangalore S, Messerli FH, Cohen JD, et al. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an International Verapamil SR-Trandolapril (INVEST) substudy. Am Heart J. 2008;156(2):241-247.
14. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
15. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19): 2421-2431.
16. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805-2816.
17. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2(3):294-302.
18. Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS I V. J Hum Hypertens. 2004;18(3):139-185.
19. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihyper-tensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32-39.
20. Kjeldsen SE, Aksnes TA, de la Sierra A, Ruilope L. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy. 2007;4(1):31-40.
21. Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, Graff A. Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther. 2007;29(1):61-73.
22. Tuomilehto J, Tykarski A, Baumgart P, Reimund B, Le Breton S, Ferber P. Combination therapy with valsartan/hydrochlorothiazide at doses up to 320/25 mg improves blood pressure levels in patients with hypertension inadequately controlled by valsartan 320 mg monotherapy. Blood Press Suppl. 2008;1:15-23.
23. Magagna A, Abdel-Haq B, Pedrinelli R, Salvetti A. Does chlortha-lidone increase the hypotensive effect of nifedipine? J Hypertens. 1986;4(Suppl 5):S519-S521.
24. Stergiou GS, Malakos JS, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring. J Cardiovasc Pharmacol. 1997;29(3):412-416.
25. Epstein BJ, Roberts ME. Managing peripheral edema in patients with arterial hypertension. Am J Ther. 2009;16(6):543-553.
26. Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim G W, Oparil S. Fixed-dose combinations in the management of hypertension: defning the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs. 2005;5(1):17-22.
27. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580.
28. Gerbino P P, Shoheiber O. Adherence patterns among patients treated with fxed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279-1283.
29. Bramley TJ, Gerbino P P, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12(3):239-245.